newsfilter
← Latest News
GlobeNewswire·

Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and